NGS Homologous Recombinant Deficiency HRR Panel
Comprehensive Genetic Cancer Risk Assessment
The NGS Homologous Recombinant Deficiency HRR Panel represents a breakthrough in personalized cancer medicine, offering unprecedented insights into your genetic predisposition to various cancers. This advanced diagnostic tool evaluates the integrity of your homologous recombination repair pathway, a critical cellular mechanism that maintains DNA stability and prevents malignant transformations.
What is Homologous Recombinant Deficiency?
Homologous recombination is an essential DNA repair process that cells use to fix double-strand breaks in DNA. When this pathway becomes deficient due to genetic mutations, cells accumulate DNA damage, significantly increasing cancer risk. The HRR pathway involves multiple genes working in concert to maintain genomic integrity, and defects in any of these components can compromise the entire repair system.
What the Test Measures and Detects
Our comprehensive NGS HRR Panel analyzes multiple key genes involved in the homologous recombination repair pathway, including:
- BRCA1 and BRCA2 genes – Primary regulators of DNA repair
- PALB2 – BRCA2 interaction partner
- RAD51 family genes – Central to recombination machinery
- ATM and ATR – DNA damage response kinases
- CHEK2 – Cell cycle checkpoint regulator
- Additional HRR pathway components
The test utilizes Next Generation Sequencing technology to provide comprehensive coverage of coding regions and critical intronic boundaries, ensuring maximum detection sensitivity for pathogenic variants, including single nucleotide variants, small insertions/deletions, and copy number variations.
Who Should Consider This Test
Clinical Indications and Risk Factors
This advanced genetic screening is particularly recommended for individuals with:
- Personal history of breast, ovarian, pancreatic, or prostate cancer diagnosed at young age
- Multiple primary cancers in the same individual
- Strong family history of cancer across generations
- Ashkenazi Jewish ancestry with cancer history
- Triple-negative breast cancer diagnosis
- Male breast cancer patients
- Individuals with pancreatic cancer regardless of family history
- Metastatic prostate cancer patients
- Unexplained clustering of cancer in family members
Benefits of Taking the HRR Panel Test
Proactive Health Management
Undergoing the NGS Homologous Recombinant Deficiency HRR Panel offers numerous advantages for your healthcare journey:
- Personalized Cancer Risk Assessment: Understand your specific genetic predisposition to various cancers
- Informed Prevention Strategies: Develop targeted screening and prevention plans based on your genetic profile
- Treatment Guidance: Identify potential responsiveness to PARP inhibitor therapies and other targeted treatments
- Family Risk Information: Provide valuable genetic information for blood relatives
- Reproductive Planning: Make informed decisions about family planning when hereditary cancer risks are identified
- Peace of Mind: Reduce uncertainty through comprehensive genetic evaluation
Understanding Your Test Results
Interpreting Genetic Findings
Your NGS HRR Panel results will be carefully analyzed and interpreted by our team of genetic specialists. Results typically fall into several categories:
- Positive Result: Identification of a pathogenic variant associated with increased cancer risk. This information enables proactive management and targeted prevention strategies.
- Negative Result: No pathogenic variants detected in the genes analyzed. This may provide reassurance, though it doesn’t eliminate all cancer risks.
- Variant of Uncertain Significance (VUS): Identification of genetic changes with unknown clinical significance. These findings require careful interpretation and may need family studies for clarification.
- Benign Variants: Common genetic variations not associated with increased cancer risk.
All results include comprehensive genetic counseling to ensure you fully understand the implications and next steps for your healthcare management.
Test Pricing and Details
| Price Type | Amount (USD) |
|---|---|
| Discount Price | $1050 |
| Regular Price | $1400 |
Test Specifications
- Turnaround Time: 4-6 weeks
- Sample Type: Peripheral blood or FFPE tissue block
- Test Components: EDTA Vacutainer (2ml)
- Methodology: Next Generation Sequencing (NGS)
- Prescription Requirement: Doctor’s prescription required (not applicable for surgery, pregnancy, or international travel cases)
Nationwide Accessibility
We have established branches across the United States, ensuring convenient access to this advanced genetic testing in all major metropolitan areas including New York, Los Angeles, Chicago, Houston, Phoenix, Philadelphia, and many other cities. Our network of certified collection centers and partnerships with leading healthcare providers guarantees that quality genetic testing is within reach regardless of your location.
Take Control of Your Genetic Health Today
Don’t leave your cancer risk to chance. The NGS Homologous Recombinant Deficiency HRR Panel provides the comprehensive genetic information needed to make informed decisions about your health and future. Our team of genetic counselors and medical professionals are ready to guide you through the testing process and help you understand your results.
Call us today at +1(267) 388-9828 to schedule your consultation and take the first step toward personalized cancer risk management.
Book your NGS Homologous Recombinant Deficiency HRR Panel test now and gain valuable insights into your genetic cancer predisposition. Our dedicated patient coordinators are available to answer your questions, assist with insurance inquiries, and help you navigate the testing process with confidence and ease.
